- 49 Downloads
Acamprosate (Campral® delayed-release tablet), a synthetic compound with a similar structure to that of the neurotransmitter GABA and the neuromodulator taurine, facilitates the maintenance of abstinence in detoxified alcohol-dependent patients. Although the precise mechanism(s) of action of the drug remains to be fully elucidated, it appears that it most likely involves beneficial modulation of the glutamatergic neurotransmitter system, including antagonism of the mGLu5 metabotropic glutamate receptor, to counteract the imbalance between the glutamatergic and GABAergic systems associated with chronic alcohol exposure and alcohol withdrawal.
In several double-blind, placebo-controlled trials of up to 12 months’ duration, acamprosate effectively maintained complete abstinence in detoxified alcohol-dependent patients, irrespective of disease severity or the type of psychosocial support. The drug showed better efficacy than placebo and was very well tolerated. Limited data from a relatively well designed trial indicate that the drug has similar efficacy to that of naltrexone and that combination therapy with these two agents provides better efficacy than acamprosate monotherapy, although multicentre direct head-to-head investigations are required to fully establish the potential of this combination. The drug may be particularly useful in those with hepatic impairment and/or liver disease. Thus, in combination with psychosocial and behavioural management programmes, acamprosate is a promising option for the maintenance of abstinence in alcohol-dependent patients after alcohol withdrawal.
Chronic alcohol exposure is thought to negatively alter the balance between the excitation of glutamatergic neurotransmitter systems and the inhibition of GABAergic neurotransmitter systems; the imbalance between these two systems is most likely associated with the development of tolerance to the effects of alcohol and alcohol-withdrawal symptomatology. Although acamprosate has a similar structure to that of GABA, in vitro and in vivo evidence suggests that key mechanism of action results from modification of the glutamatergic neurotransmitter system, particularly via modulation of activity at the NMDA receptor that is possibly mediated through modulation of the polyamine receptor site and/or via antagonism at the metabotropic mGlu5 receptor. In various animal models, acamprosate dose-dependently reduces acute and chronic alcohol self-administration and blocks the alcohol withdrawal-induced increase in glutamate. In in vitro studies, it reduced glutamate-induced neurotoxicity associated with alcohol withdrawal in cortical and hippocampal cell cultures and attenuated (±)-l-amino-cyclopentane-trans-l, 3-dicarboxylic acid (trans-ACPD)-induced neurotoxicity as seen in hippocampal slices from rats that had been chronically exposed to ethanol.
Peak plasma concentrations were achieved 5.5–7.3 hours after administration of oral acamprosate 1998 mg/day, with steady-state plasma concentrations achieved within 5 days. Bioavailability is low (absolute bioavailability ≈11%) and protein binding is negligible. The drug is widely distributed throughout the body (volume of distribution after intravenous administration is ≈1 L/kg [72–109L]); animal studies have shown that the drug can cross the blood-brain barrier. Acamprosate is not metabolised and is primarily excreted via the kidneys as unchanged drug, with a mean terminal elimination half-life of 18–33 hours. The pharmacokinetics of acamprosate are not affected by hepatic impairment. Total body and renal clearances of the drug are significantly reduced in renal impairment; dosage adjustments are required in patients with moderate renal impairment and the drug is contraindicated in those with severe renal impairment. No clinically relevant interactions are seen when the drug is coadministered with alcohol or medications used to treat alcohol dependence or common co-morbidities in this patient population, such as disulfiram, naltrexone, diazepam or imipramine.
Acamprosate, in combination with psychosocial therapy, was generally significantly more effective than placebo at maintaining complete abstinence in well designed trials of 3–12 months’ duration enrolling ≈3500 alcohol-dependent patients aged 18–65 years. In double-blind trials, treatment for 6 months’ with oral acamprosate 1332–1998 mg/day (dosage based on bodyweight) was generally associated with significantly more patients remaining completely abstinent (12–48% vs 11–33%), a longer mean cumulative abstinence duration (CAD; 61–110 vs 43–89 days), and a longer median time to first drink (TFD; 45–151 vs 15–61 days) than placebo. Where reported, after 6 months’ post-treatment follow-up, the beneficial effect of acamprosate on mean CAD was maintained. In addition, in a 3-month trial, acamprosate 1332 mg/day treatment was as effective as acamprosate 1998 mg/day in maintaining complete abstinence, with both dosages being more effective than placebo (acamprosate dosage given irrespective of bodyweight). Longer term placebo-controlled trials (11–12 months’ treatment) generally confirmed the superiority of acamprosate 1332–1998 mg/day over placebo in terms of abstinence endpoints. Significantly more acamprosate than placebo recipients remained completely abstinent (18–45% vs 7–25%) and the mean CAD was significantly longer in the acamprosate arms (175–225 vs 104–162 days). In general, the mean CAD remained significantly longer in acamprosate recipients during the 6- to 12-month post-treatment follow-up period.
Furthermore, coadministration of acamprosate and naltrexone was more effective in maintaining complete abstinence than acamprosate alone. In this 3-month, single-centre trial (n = 40 patients/group), the probability towards the first drink was significantly lower with acamprosate 1998 mg/day, naltrexone 50 mg/day or acamprosate plus naltrexone than with placebo in alcohol-dependent patients, with acamprosate plus naltrexone being more effective than acamprosate alone at preventing relapse to heavy drinking. In terms of maintaining complete abstinence (i.e. mean TFD; secondary endpoint), there was no intergroup difference between acamprosate 1665–1998 mg/day and naltrexone 50 mg/day in a 1-year single-blind study in alcohol-dependent patients; nevertheless, acamprosate was not as effective as naltrexone in terms of mean CAD or mean time to heavy drinking (primary endpoints).
Acamprosate is very well tolerated in abstinent alcohol-dependent patients. The incidence of adverse events with acamprosate was similar to that with placebo in clinical trials, with the exception of diarrhoea, which was the most frequently reported adverse event in either treatment group (16% vs 10%; no statistical analysis reported). Results from pooled pre- and postmarketing analyses in >7000 patients who received the drug for up to 1 year confirmed the good tolerability of acamprosate.
KeywordsAlcohol Dependence Naltrexone Alcohol Withdrawal Disulfiram Acamprosate
- 1.Pelc I, Ansoms C, Lehert P, et al. The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcohol Clin Exp Res 2002; 26(10): 1529–38PubMedCrossRefGoogle Scholar
- 3.Dongier M. Brain, alcohol and alcoholism treatment. Ann R Coll Physicians Surg Can 1993; 26(1): 26–8Google Scholar
- 7.De Witte P, Littleton J, Parot P, et al. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs (in press)Google Scholar
- 10.Forest Pharmaceuticals Inc. CAMPRAL® (acamprosate calcium) delayed-release tablets prescribing information [online]. Available from URL: http://www.campral.com [Accessed 2005 Apr 11]
- 13.Harris BR, Gibson A, Prendergast MA, et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippo-campal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcohol Clin Exp Res 2003; 27(11): 1724–35PubMedCrossRefGoogle Scholar
- 16.Spanagel R, Putzke J, Schobitz B, et al. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 1996; 305: 45–50Google Scholar
- 26.Durbin P, Hulot T, Chabac S. Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In: Soyka M, editor. Acamprosate in relapse prevention of alcoholism. Proceedings of the 1st Campral-symposium ESBRA Stuttgart. Germany, Springer 1995, 47–64Google Scholar
- 36.Barrias JA, Chabac S, Fereirra L, et al. Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study [in Portuguese]. Psiquiatria Clinica 1997; 18(2): 149–60Google Scholar
- 43.US FDA Center for Drug Evaluation and Research. NDA 21–431: acamprosate calcium tablets [online]. Available from URL: http://www.fda.gov [Accessed 2005 May 3]
- 46.Merck Pharmaceuticals. Campral® EC: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2005 Apr 26]
- 48.Scottish Intercollegiate Guidelines Network. The management of harmful drinking and alcohol dependence in primary care: a national clinical guideline [online]. Available from URL: http://www.sign.ac.uk [Accessed 2005 Apr 12]
- 50.Management of Substance Use Disorders Working Group. VHA/DoD clinical practice guideline for the management of substance use disorders, Washington (DC): Veterans Health Administration, Department of Defence [online]. Available from URL: http://www.guideline.gov [Accessed 2005 Apr 12]
- 52.UK Alcohol Forum. UK alcohol forum guidelines [online]. Available from URL: http://www.ukalcoholforum.org [Accessed 2005 Apr 26]
- 53.American Society of Health-System Pharmacists. Naltrexone hydrochloride. In: McEnvoy GK, editor. American Hospital Formulary Services Drug Information. Bethesda (MD): Datapharma Publications Limited, 2005: 2108–15Google Scholar
- 54.American Society of Health-System Pharmacists. Disulfiram. In: McEnvoy GK, editor. American Hospital Formulary Services Drug Information. Bethesda (MD): Datapharma Publications Limited, 2005: 3558–9Google Scholar